Stockscreener 앱 받기
6.18
0.16%
-0.01
시장 영업 전:
6.22
0.04
+0.65%
Certara Inc 주식(CERT)의 최신 뉴스
Certara (CERT) Sells Regulatory and Medical Writing Business for Up to $135M - Yahoo Finance
Veristat expands with Certara acquisition - BioXconomy
Certara (CERT) price target decreased by 23.74% to 9.63 - MSN
AI in Predictive Toxicology Research Report 2026 Featuring - GlobeNewswire
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, ChemaxonGlobal Forecast to 2030 and 2035 - Yahoo Finance
Certara strategic business divestiture comes at right time, says analyst - MSN
Certara | D: Filing D - Moomoo
Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates - MSN
Certara to sell regulatory and medical writing business for up to $135M - MSN
How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations - Yahoo Finance
Wall Street analysts think Certara (CERT) could surge 43.28%: Read this before placing a bet - MSN
Certara: An Interesting Situation To Keep Track Off (NASDAQ:CERT) - Seeking Alpha
CERT Price Today: Certara, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
(CERT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Barclays Remains a Hold on Certara (CERT) - The Globe and Mail
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst - Sahm
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report? - MSN
CERT Certara posts 8.8 percent year-over-year Q4 2025 revenue growth despite sizeable EPS miss pressuring shares.Barrier to Entry - UBND thành phố Hải Phòng
Certara to Divest Regulatory and Medical Writing Business - The Globe and Mail
Certara to sell regulatory writing unit to Veristat for $135M By Investing.com - Investing.com India
Is Certara (CERT) stock considered stable (+2.26%) 2026-04-22Price Surge - Cổng thông tin điện tử tỉnh Lào Cai
Certara (CERT) Sells Regulatory Writing Business for Up to $135 Million - GuruFocus
Veristat to Acquire Certara’s Regulatory and Medical Writing Business - Business Wire
William Blair Maintains Certara(CERT.US) With Hold Rating - Moomoo
Veristat, LLC signed a definitive agreement to acquire Regulatory and Medical Writing business of Certara, Inc for approximately $140 million. - marketscreener.com
Craig-Hallum Initiates Certara(CERT.US) With Hold Rating - Moomoo
Certara Shares Rise Amid Plan to Sell Portion of Business to Veristat - Moomoo
Certara to Sell Regulatory and Medical Writing Business to Veristat for Up to $135 Million, Refocuses on Model-Informed Drug Development 1 - Minichart
Certara to sell regulatory writing unit to Veristat for $135M - Investing.com
Certara to Sell Regulatory, Medical Writing Business to Veristat for $135 Million - marketscreener.com
Certara : Regulatory and Medical Writing – Supplemental Information - marketscreener.com
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat - The Manila Times
Certara to Sell Global Medical Writing Business to Veristat for $100M, Plus Up to $35M Earn-Out - TradingView
Certara (NASDAQ: CERT) divests regulatory and medical writing unit to Veristat - Stock Titan
Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH) - The Globe and Mail
Certara, Inc. $CERT Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
1.66%
1.60%
자본화:
|
볼륨(24시간):